Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer

Chad A. Hamilton; G. Larry Maxwell; Mildred R. Chernofsky; Sarah A. Bernstein; John H. Farley; G. Scott Rose

doi:10.1016/j.ygyno.2008.04.028

Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer

Chad A. Hamilton^*, G. Larry Maxwell, Mildred R. Chernofsky, Sarah A. Bernstein, John H. Farley, G. Scott Rose

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

84 Scopus citations

Abstract

Background: Malignant ascites often has a profound impact on the quality of life of patients with refractory ovarian cancer. Current treatments, including dietary, medical, and procedural are often temporary and unsatisfactory options in patients approaching the end of life. Case: We present a case of an 88 year-old receiving home hospice care with refractory ovarian cancer and severe symptomatic ascites. We performed a paracentesis and treated her with intraperitoneal bevacizumab with dramatic improvement in her ascites and the quality of her final weeks of life. Conclusion: Intraperitoneal bevacizumab may be a useful tool in the palliation of malignant ascites and is worthy of further study.

Original language	English
Pages (from-to)	530-532
Number of pages	3
Journal	Gynecologic Oncology
Volume	111
Issue number	3
DOIs	https://doi.org/10.1016/j.ygyno.2008.04.028
State	Published - Dec 2008
Externally published	Yes

Keywords

Ascites
Bevacizumab
Intraperitoneal
Ovarian cancer
Palliation

Access to Document

10.1016/j.ygyno.2008.04.028

Cite this

@article{dbc867d90bfe4629893a2685199683d4,

title = "Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer",

abstract = "Background: Malignant ascites often has a profound impact on the quality of life of patients with refractory ovarian cancer. Current treatments, including dietary, medical, and procedural are often temporary and unsatisfactory options in patients approaching the end of life. Case: We present a case of an 88 year-old receiving home hospice care with refractory ovarian cancer and severe symptomatic ascites. We performed a paracentesis and treated her with intraperitoneal bevacizumab with dramatic improvement in her ascites and the quality of her final weeks of life. Conclusion: Intraperitoneal bevacizumab may be a useful tool in the palliation of malignant ascites and is worthy of further study.",

keywords = "Ascites, Bevacizumab, Intraperitoneal, Ovarian cancer, Palliation",

author = "Hamilton, {Chad A.} and Maxwell, {G. Larry} and Chernofsky, {Mildred R.} and Bernstein, {Sarah A.} and Farley, {John H.} and Rose, {G. Scott}",

year = "2008",

month = dec,

doi = "10.1016/j.ygyno.2008.04.028",

language = "English",

volume = "111",

pages = "530--532",

journal = "Gynecologic Oncology",

issn = "0090-8258",

number = "3",

}

TY - JOUR

T1 - Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer

AU - Hamilton, Chad A.

AU - Maxwell, G. Larry

AU - Chernofsky, Mildred R.

AU - Bernstein, Sarah A.

AU - Farley, John H.

AU - Rose, G. Scott

PY - 2008/12

Y1 - 2008/12

N2 - Background: Malignant ascites often has a profound impact on the quality of life of patients with refractory ovarian cancer. Current treatments, including dietary, medical, and procedural are often temporary and unsatisfactory options in patients approaching the end of life. Case: We present a case of an 88 year-old receiving home hospice care with refractory ovarian cancer and severe symptomatic ascites. We performed a paracentesis and treated her with intraperitoneal bevacizumab with dramatic improvement in her ascites and the quality of her final weeks of life. Conclusion: Intraperitoneal bevacizumab may be a useful tool in the palliation of malignant ascites and is worthy of further study.

AB - Background: Malignant ascites often has a profound impact on the quality of life of patients with refractory ovarian cancer. Current treatments, including dietary, medical, and procedural are often temporary and unsatisfactory options in patients approaching the end of life. Case: We present a case of an 88 year-old receiving home hospice care with refractory ovarian cancer and severe symptomatic ascites. We performed a paracentesis and treated her with intraperitoneal bevacizumab with dramatic improvement in her ascites and the quality of her final weeks of life. Conclusion: Intraperitoneal bevacizumab may be a useful tool in the palliation of malignant ascites and is worthy of further study.

KW - Ascites

KW - Bevacizumab

KW - Intraperitoneal

KW - Ovarian cancer

KW - Palliation

UR - http://www.scopus.com/inward/record.url?scp=56449083663&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2008.04.028

DO - 10.1016/j.ygyno.2008.04.028

M3 - Article

C2 - 18561992

AN - SCOPUS:56449083663

SN - 0090-8258

VL - 111

SP - 530

EP - 532

JO - Gynecologic Oncology

JF - Gynecologic Oncology

IS - 3

ER -

Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer

Abstract

Keywords

Access to Document

Fingerprint

Cite this